【摘要】 目的观察质子泵抑制剂奥美拉唑、雷贝拉唑对胃食管反流病(GERD)的疗效。方法筛选具有烧心和反流症状并经内镜证实食管下段有黏膜损伤的GERD患者200例,随机分两组OAC 101例口服奥美拉唑20 mg每天2次、治疗4周;RAC 99例口服雷贝拉唑20 mg每天2次,治疗4周。每周随访1次,分别于2周和4周评价疗效。结果两组在治疗结束后,临床症状改善及内镜表现差异有高度统计学意义,P<0.01。但总体疗效并非十分理想,个体差异大。结论本研究结果提示细胞色素P4502C19(CYP2C19)是PPI在肝脏代谢的主要途径,其基因型是导致药物疗效的个体差异的直接因素,为今后研究PPI治疗GERD的疗效及与CYP2C19基因多态性的关系打下基础。更多还原

【Abstract】 Objective To observe the effects of Omeprazole and Rabeprazole on GERD.Methods All of 200 patients with GERD were randomly divided into two groups,101 patients in omeprazole group orally received omeprazole 20 mg,2 times a day,for 4 weeks and 99 patients in rabeprazole orally received rabeprazole 20 mg,2 times a day,for 4 weeks.Clinical efficacy was observed in patients of both groups after a treatment course of 2 weeks and 4 weeks.Results The rates of efficacy in patients of Rabeprazole group and Omeprazole group were 79.79% and 60.39%,then their marked effectiveness rates in endoscopic were 84.84% and 64.35% respectively.There was significant difference between two groups(P < 0.01).Thus the overall effect was not satisfied,founding marked individual differences.This results prompt Cytochrome P4502C19(CYP2C19) is the main way of PPI metabolism in the liver,the genotype is the leading cause of drug efficacy of individual differences in the direct factors,for future studies of PPI therapy for the treatment of GERD and CYP2C19 gene polymorphism and lay the foundation.更多还原